150 related articles for article (PubMed ID: 29103203)
1. Cancer-Specific Survival Stratification Derived from Tumor Expression of Tissue Inhibitor of Metalloproteinase-2 in Non-Metastatic Renal Cell Carcinoma.
Beardo P; Truan Cacho D; Izquierdo L; Alcover-Garcia JB; Alcaraz A; Extramiana J; Mallofré C
Pathol Oncol Res; 2019 Jan; 25(1):289-299. PubMed ID: 29103203
[TBL] [Abstract][Full Text] [Related]
2. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
5. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
6. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
Lein M; Jung K; Laube C; Hübner T; Winkelmann B; Stephan C; Hauptmann S; Rudolph B; Schnorr D; Loening SA
Int J Cancer; 2000 Mar; 85(6):801-4. PubMed ID: 10709099
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma.
Kara O; Maurice MJ; Zargar H; Malkoc E; Akca O; Andrade HS; Ramirez D; Caputo PA; Nelson RJ; Rini B; Kaouk JH
Int Urol Nephrol; 2016 Aug; 48(8):1253-1260. PubMed ID: 27215555
[TBL] [Abstract][Full Text] [Related]
8. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
9. The balance between MMP-2/-9 and TIMP-1/-2 is shifted towards MMP in renal cell carcinomas and can be further disturbed by hydrogen peroxide.
Hemmerlein B; Johanns U; Halbfass J; Böttcher T; Heuser M; Radzun HJ; Thelen P
Int J Oncol; 2004 May; 24(5):1069-76. PubMed ID: 15067327
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Schwandner O; Schlamp A; Broll R; Bruch HP
Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.
Mytsyk Y; Borys Y; Tumanovska L; Stroy D; Kucher A; Gazdikova K; Rodrigo L; Kruzliak P; Prosecky R; Urdzik P; Dosenko V
Clin Exp Med; 2019 Nov; 19(4):515-524. PubMed ID: 31440867
[TBL] [Abstract][Full Text] [Related]
12. Validation of a postoperative prognostic model consisting of tumor microvascular invasion, size, and grade to predict disease-free and cancer-specific survival of patients with surgically resected renal cell carcinoma.
May M; Brookman-Amissah S; Kendel F; Knoll N; Roigas J; Hoschke B; Miller K; Gilfrich C; Pflanz S; Gralla O
Int J Urol; 2009 Jul; 16(7):616-21. PubMed ID: 19456988
[TBL] [Abstract][Full Text] [Related]
13. Clinical and oncological outcomes in Chinese patients with renal cell carcinoma and venous tumor thrombus extension: single-center experience.
Chen X; Li S; Xu Z; Wang K; Fu D; Liu Q; Wang X; Wu B
World J Surg Oncol; 2015 Feb; 13():14. PubMed ID: 25650039
[TBL] [Abstract][Full Text] [Related]
14. Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC).
Capitanio U; Suardi N; Matloob R; Roscigno M; Abdollah F; Di Trapani E; Moschini M; Gallina A; Salonia A; Briganti A; Montorsi F; Bertini R
BJU Int; 2014 Aug; 114(2):210-5. PubMed ID: 24854206
[TBL] [Abstract][Full Text] [Related]
15. Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential.
Miyake H; Hara I; Gohji K; Yamanaka K; Hara S; Arakawa S; Nakajima M; Kamidono S
Clin Cancer Res; 1999 Oct; 5(10):2824-9. PubMed ID: 10537348
[TBL] [Abstract][Full Text] [Related]
16. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
17. Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging.
Yu KJ; Keskin SK; Meissner MA; Petros FG; Wang X; Borregales LD; Gu C; Tamboli P; Matin SF; Wood CG; Karam JA
Cancer; 2018 Oct; 124(20):4023-4031. PubMed ID: 30276798
[TBL] [Abstract][Full Text] [Related]
18. Small renal cell carcinomas--how dangerous are they really? Results of a large multicenter study.
Steffens S; Junker K; Roos FC; Janssen M; Becker F; Henn D; Wegener G; Siemer S; Hofmann R; Schrader M; Stöckle M; Thüroff JW; Hartmann A; Kuczyk MA; Schrader AJ;
Eur J Cancer; 2014 Mar; 50(4):739-45. PubMed ID: 24321262
[TBL] [Abstract][Full Text] [Related]
19. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
[TBL] [Abstract][Full Text] [Related]
20. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
